OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
October 12, 2022
Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).
Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.
October 05, 2022
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).